Company profilePharmaceutical#533 of 1,318 in Pakistan✓ No DRAP alerts

A. J. MIRZA

Pharmaceutical company · 24 brands · 37 molecules

Ranked #10 of 44 companies in Antineoplastics

24 registered products 16 pharmaceutical brands 37 distinct molecules 0 DRAP alerts

Company overview

24
registered products
16
pharmaceutical brands
37
distinct molecules
9
therapeutic classes
0
DRAP alerts

A. J. MIRZA is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 24 product registrations across 37 distinct molecules. Its portfolio is concentrated in Antineoplastics and Antivirals For Systemic Use. It has no DRAP recall, shortage or safety notices on record.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Products by A.

17 products matched in our catalogue — each with its observed price and DRAP approved ceiling.

Endocrine Hormone Therapy 1
Antivirals For Systemic Use 1

Price ceiling age

DRAP sets a maximum price per registration and revises it only on application. In a market with high inflation, an old ceiling erodes margin in real terms.

17
ceilings with an approval date
0
not revised in 2+ years
2025
oldest approval year
202517

Top molecules by brand count

Stavudine3 brands
Nevirapine2 brands
Lamivudine2 brands
Vinblastine Usp 1Mg1 brand
Didanosine1 brand

Therapeutic classes

Antineoplastics · 9Antivirals For Systemic Use · 7Drugs For Treatment Of Bone Diseases · 2Endocrine Hormone Therapy · 2Quinolone Antibacterials · 1Drugs For Peptic Ulcer And Gastro-Oesophageal Reflux Disease (Gord) · 1Other Beta-Lactam, Cephalosporins & Penems · 1Cancer · 1Antimycotics Systemic Use · 1

Conditions treated

Oncology · 1

Price band (DRAP official ceilings)

Registered products priced by source
DRAP-official12 products · Rs 361.8 – Rs 30,005
Servaid1 products · Rs 1,700 – Rs 1,700
Median across source: Rs 7,405.66

Regulatory record

No DRAP alerts on record

No recalls, shortage notices or safety alerts involving this company’s products appear in the DRAP alert feed we track. Median across all 1,318 mapped companies is zero — 1,165 of them also have a clean sheet.

Competitive set

Companies whose registered portfolio overlaps most with this one.

Portfolio whitespace

Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.

Pharmasol (Pvt) Ltd. holds 110 molecules not in this portfolio
AcetazolamideAcyclovirAlpha KetoanaloguesAnastrazoleAnastrozoleAprepitant
Pharmedic Pharmaceuticals Industries (Pvt.) Ltd. holds 87 molecules not in this portfolio
Actinomycin DAlbendazoleAmitriptylineAmlodipineAmoxicillin BaseArtemether
AGP (PRIVATE) LTD. holds 142 molecules not in this portfolio
AmikacinAminophyllineAmlodipineAmoxicillinAprepitantArtemether

Get the full profile for A.

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.